PCM
AQST icon

Penn Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Penn Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-115,936
Closed -$749K – 174
2025
Q4 		$749K Buy
115,936
+23,028
+25% +$143K 0.06% 122
2025
Q3 		$519K Buy
92,908
+5,793
+7% +$25K 0.04% 147
2025
Q2 		$288K Buy
87,115
+497
+0.6% +$1.43K 0.02% 146
2025
Q1 		$251K Buy
+86,618
New +$262K 0.02% 152

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Penn Capital Management's AQST Position: Q1 2026 in Review

Penn Capital Management sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 115,936 shares — an estimated $749K sold.

Penn Capital Management first reported a position in AQST in Q1 2025 and held it in 4 quarters. The position peaked at $749K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Penn Capital Management reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Penn Capital Management sold 115,936 Aquestive Therapeutics shares in Q1 2026, an estimated $749K.
  • Penn Capital Management first reported a position in Aquestive Therapeutics in Q1 2025 and held it in 4 quarters.
  • Penn Capital Management's Aquestive Therapeutics position peaked at $749K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Penn Capital Management's 13F filing for Q1 2026, filed 7 May 2026.